The Effects of 12-Week Hydrogen-Rich Water Intake on Body Composition, Short-Chain Fatty Acids Turnover, and Brain Metabolism in Overweight Adults: A Randomized Controlled Trial
Darinka Korovljev, Dejan Javorac, Nikola Todorovic, Marijana Ranisavljev, Dagrun Engeset, Tonje Holte Stea, Jelena Ostojic, Katarina Bijelic, Branislava Srdjenovic Conic, Nebojsa Kladar, Laszlo Ratgeber, Nenad Trunic, Sava Rajkovic, Valdemar Stajer, Sergej M. Ostojic · CURRENT TOPICS IN NUTRACEUTICAL RESEARCH · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In with a body mass index >24, the mean fecal calprotectin levels were significantly reduced after hydrogen-rich water intervention for 19.7 μg/mg (95% confidence interval, from 0.31 to 39.09) (P = 0.03). These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in with a body mass index >24. The mean fecal calprotectin levels were significantly reduced after hydrogen-rich water intervention for 19.7 μg/mg (95% confidence interval, from 0.31 to 39.09) (P = 0.03).
What the Researchers Studied
The researchers studied with a body mass index >24. The study used a randomized human clinical trial.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 195.6 µM H₂ (≈0.394 mg/L); Source-reported hydrogen exposure: 0.5 L hydrogen-rich water/day; dissolved H₂ concentration was not sufficiently reported, so H2HUBB did not estimate milligrams of H₂; H2HUBB calculated daily H₂ dose: approximately 0.2 mg H₂/day, calculated from the source-reported dissolved H₂ concentration and total hydrogen-water volume consumed per day. The mean fecal calprotectin levels were significantly reduced after hydrogen-rich water intervention for 19.7 μg/mg (95% confidence interval, from 0.31 to 39.09) (P = 0.03).
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was with a body mass index >24. The reported sample size was 10. The study used a randomized human clinical trial. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen concentration was 195.6 µM H₂ (≈0.394 mg/L). The source-reported hydrogen exposure was 0.5 L hydrogen-rich water/day; dissolved H₂ concentration was not sufficiently reported, so H2HUBB did not estimate milligrams of H₂. H2HUBB calculated daily H₂ dose: approximately 0.2 mg H₂/day, calculated from the source-reported dissolved H₂ concentration and total hydrogen-water volume consumed per day. This is a deterministic dose translation, not a separately measured value.
Limitations and Safety
No separate limitations or safety findings were identified in the current-study source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base. The original scholarly source is available at https://openurl.ebsco.com/contentitem/gcd:169836158?sid=ebsco:plink:crawler-gcd&id=ebsco:gcd:169836158&crl=c&jrnl=15407535.